相关实验视频

Updated: Jul 18, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

探索使用西尔德纳菲尔治疗高脂肪饮食引起的勃起功能障碍的应用,该疗法基于交叉蛋白-18介导的NLRP3/Caspase-1信号通路

Bingbing Zhu¹, Yangjiu Niu¹, Lipan Niu¹

¹Department of Human Anatomy, School of Basic Medical Science, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, 830011, China.

Sexual medicine

|August 28, 2023

概括

西尔德纳菲尔通过减少炎症来改善勃起功能障碍 (ED). 这项研究表明,在患有饮食引起的ED的老鼠中,西尔代纳菲尔抑制了炎症通路的关键路径 - - 炎症灭亡.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
药理学药理学是指药理学的学科.
炎症研究炎症研究

背景情况:

炎症是心脏病和勃起功能障碍 (ED) 的重要危险因素.
西尔德纳菲尔是一种固酶5型抑制剂,具有抗氧化特性.
介素-18 (IL-18) 是一种促炎因素,与病理性炎症有关.

研究的目的:

在高脂肪饮食诱导ED的老鼠模型中评估西尔代纳菲尔对勃起功能的治疗效果.
调查西尔代纳菲尔作用的潜在机制,重点关注NLRP3介导的烧亡途径.

主要方法:

雄性Sprague Dawley大鼠被分为控制,ED,西尔代纳菲尔,IL-18和IL-18+西尔代纳菲尔组.
通过测量洞内压力和平均动脉压力来评估勃起功能.
分析了内皮氧化合成酶的表达, pyroptosis 因素 (NLRP3,caspase-1,gasdermin D) 和光滑肌细胞与原纤维的比例.

主要成果:

西尔德纳菲尔显著改善勃起功能,通过增加洞内与平均动脉压的比率来表明.
西尔德纳菲尔治疗导致内皮氧化合成酶的表达增加和更高的光滑肌细胞与原纤维的比率.
西尔德纳菲尔的干预显著降低了NLRP3,caspase-1和gasdermin D的表达,这些都是火死途径的关键组成部分.

结论:

西尔德纳菲尔通过减轻炎症来改善勃起功能障碍的潜力.
这项研究表明,西尔代纳菲尔通过NLRP3 / caspase-1热致死途径起作用,以减少饮食诱导的ED大鼠中的IL-18诱导的炎症.
需要进一步的临床研究来证实这些发现在人类患者中.

关键词:

它们的IL-18型.在NLRP3中,NLRP3是NLRP3中的一个.作为PDE5抑制剂的使用.这是勃起功能障碍.这种药物是西尔代纳菲尔.

更多相关视频

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Nitric Oxide Signaling Pathway

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...